The main efficacy and mechanism of action of Zilucoplan

Zilucoplan is a new complement C5 inhibitor. Its main mechanism of action is to block the cleavage of the C5 protein in the complement system and prevent the production of its downstream active fragments C5a and C5b, thereby terminating the formation of the membrane attack complex (MAC). This mechanism is of great significance in the treatment of immune diseases driven by abnormal activation of the complement system, such as generalized myasthenia gravis (gMG; a rare disease). Different from traditional complement inhibitors such as eculizumab, zeleptide is a synthetic peptide drug that is administered by subcutaneous injection, which can achieve higher treatment convenience, reduce dependence on hospital injections, and allow patients to complete the treatment process at home.

The main effect of zeleptide is reflected in its precise regulation of the pathological links of neuromuscular junction diseases such as gMG. In patients with gMG, autoantibodies act on acetylcholine receptors, activating the complement system and causing damage to the neuromuscular junction, manifesting as muscle weakness and fatigue. Zeleptide inhibits complement-mediated cell membrane attack and inflammatory response by blocking C5 activation, thereby effectively relieving myasthenic symptoms, improving muscle function, and improving patients' daily living ability and quality of life.

In addition, Zeleptide has the characteristics of rapid onset of action, and some patients can feel relief of symptoms in the early stages of medication. At the same time, the drug molecule is stable and has good pharmacokinetic properties, avoiding the risk of immune reactions that antibody drugs may cause. Its safety has also been verified in multiple international studies. Common adverse reactions are mostly slight redness and swelling at the injection site or allergic reactions, and the overall tolerance is good.

In general, zeleptide , as a highly selective modulator of the C5 complement pathway, not only has good therapeutic effects, but also expands the flexibility and versatility of complement therapy in clinical application due to its synthetic peptide structure and subcutaneous injection method.

Reference materials:https://www.drugs.com/zilucoplan.html